Stock-market dispatch — 2026-08-04

Headless run (Tue). Research output, not advice — brain never trades. Marks are live 08-04 intraday twelvedata quotes; 49/49 priced, 0 429s. Weekly ledger (4d) not due (last full run Fri 07-31; next ~Fri 08-07). Supabase upsert + push are performed by the wrapper, not this run.

Top of mind

A marquee-investor deep-dive and an independent analyst both diagnose the late-July AI drawdown the way the book already did — a credit-fear/flow event on accelerating fundamentals — and hand the consumption-compute leg (MU/TSM) fresh support. gavin-baker (Atreides, on Invest Like the Best) stress-tested the bear case and concluded "credit is the only real concern": "however you cut it — GPU availability, GPU rental pricing, the spot price of DRAM this month, token growth — everything has actually accelerated." His load-bearing new mechanism: the contracted installed base of compute trades at a massive discount to spot, and reprices up as contracts roll off — so even modest monetization funds the build-out from operating cash flow and "takes 700 billion of credit demand out," lowering the mega-issuance-peak-to-ai-capex-derate fire-probability. dwarkesh-patel (no compute book) independently confirms the price direction (spot compute +40% off the Feb trough; Google paying SpaceX $900M/mo for 110k GPUs at 2× spot) and — the semicap read — names building ASML EUV machines as the binding compute ceiling to 2030 (1.2× of the 3×/yr; N3 AI-wafer allocation going 60%→86% "by the end of next year"). This is independent, cross-source-type corroboration for token-price-inflation-favors-asset-heavy-compute, ai-roi-reckoning, and the high-conviction picks-and-shovels-leading-edge-fab-buildout. Separately, ARM Q1 FY2027 (first-party) advanced vera-cpu-to-arm-datacenter-royalty low-med→med: datacenter royalty "continues to more than double YoY," Arm AGI CPU demand ">$2B" with capacity "secured for the $1B opportunity" — a second, direct-silicon capture path atop the royalty. 5 sources ingested, 1 mechanism materially strengthened, 4 concepts corroborated, 0 novel chains, 0 calibrations. Tape bounced broadly (AMZN +4.6%, ETN +5.5% at 52w hi; uranium/space +6–11%).

Strongest-conviction buys

Ranked shortlist (4c). Prices 08-04 intraday, twelvedata.

#	Ticker	Causal chain (mechanism)	Conviction	Valuation vs base	Fundamentals (one line)	Next catalyst
1	MU	hbm-cowos-as-binding-bottleneck	High (0.80)	Yes — $829.50 (+0.8%, −34% off hi)	~6× fwd; HBM booked thru CY2027; Baker: DRAM spot up + demand accelerating = the consumption-compute demand that sells HBM	HBM4 ramp / SK Hynix reads
2	CCJ	ai-capex-to-power-and-materials-cascade + kazatomprom-supply-cut-to-western-uranium-premium	Med-high (0.73/0.60)	Yes — $89.72 (+3.9%, −34% off hi)	Term price "mid-$90s on very little demand → three digits"; 91 AP1000 pipeline; net-cash	Definitive AP1000 agreements (DOE+utilities)
3	PWR	pwr-transformer-moat-to-eps-doubling	Med-high (0.73)	Marginal — $680.20 (+1.9%, −14% off hi)	Q2 blowout (record $53B backlog, HICO breaker moat); FY EPS $16.45–16.95	Q3 backlog conversion
4	NOW	agentic-ai-seat-erosion-to-saas-rerate	Med-high (0.62)	Yes — $114.19 (+2.7%, −41% off hi)	Q2 beat+raise held; base $140–150 (~+30%); FCF-positive	Q3 print; ACV conversion
5	TSM	hbm-cowos-as-binding-bottleneck	Med-high (0.70)	Marginal — $406.11 (+0.5%, −15% off hi)	~50%+ GM; Dwarkesh: N3 AI-allocation 60→86% + ASML EUV the binding ceiling → structurally sold-out leading edge	N2 ramp / CoWoS capacity

⚠ Near-misses → watchlist: LIN (0.78) $480.46 (+0.4%) — high conviction but priced/margin-miss, helium optionality unconverted to early 2027. ARM (0.48, ↑ today) $239.06 — Q1 print strengthened the chain but conviction below the top tier. AMZN (0.50) $284.02 (+4.6%, −1% off hi) — the live +19% sector-excess winner, but priced near highs. VLO (0.52) $307.54 (−1.7%) — crack trade, priced.

Watchlist

Ticker	Thesis	Conviction	Price	Undervalued vs base?	Next catalyst
MU	hbm-cowos-as-binding-bottleneck	High	$829.50 (+0.8%)	Yes	HBM4 ramp
CCJ	kazatomprom-supply-cut-to-western-uranium-premium	Med-high	$89.72 (+3.9%)	Yes	AP1000 definitive agreements
PWR	pwr-transformer-moat-to-eps-doubling	Med-high	$680.20 (+1.9%)	Marginal	Q3 backlog
NOW	agentic-ai-seat-erosion-to-saas-rerate	Med-high	$114.19 (+2.7%)	Yes	Q3 print
TSM	hbm-cowos-as-binding-bottleneck	Med-high	$406.11 (+0.5%)	Marginal	N2 / CoWoS
ARM	vera-cpu-to-arm-datacenter-royalty	Medium (↑)	$239.06 (−0.3%)	Marginal	AGI-CPU silicon ramp (FY2028 split-out)
LIN	ras-laffan-halt-to-lin-helium-pricing-power	High	$480.46 (+0.4%)	Marginal	Helium normalization (early 2027)

Undervalued candidates (today)

hbm-cowos-as-binding-bottleneck — MU −34% off hi while Gavin Baker independently confirms the demand leg (DRAM spot up, GPU rentals +50–60% in 6–7 months) it rides.
ai-capex-to-power-and-materials-cascade — CCJ +3.9% but still −34% off hi; term-price thesis doesn't depend on the Q2 EPS miss; live cascade sector-excess only −1.3%.
agentic-ai-seat-erosion-to-saas-rerate — NOW $114.19, −41% off hi, FCF-positive; base $140–150.

New chains to investigate (hypothesis-stage)

None net-new today. Breadth (ai-infra 47% ⚠ over) steered net-new away from AI-infra; the day's fresh AI-infra material mapped onto existing chains (well-connected wiki — the healthy case, gaining independent legs). The breadth-serving source (Biotech Hangout, healthcare) folded into us-biotech-strategic-technology-offshoring rather than a net-new tradeable chain (the LOE→M&A floor is a known theme).

New theses (now active)

None net-new. (ARM/vera-cpu-to-arm-datacenter-royalty was already active-adjacent; it strengthened rather than newly activated — see below.)

Updated theses (existing active)

vera-cpu-to-arm-datacenter-royalty — low-med→med; as_of→08-04. ARM Q1 FY2027 first-party: datacenter royalty "continues to more than double YoY" (durable, fresh quarter), AGI CPU demand ">$2B" with capacity secured for $1B, CPU TAM $100B→$220B, and a direct-silicon capture path (Arm's own AGI CPU) that partially answers the Wei ISA-neutral caveat. Emitted (ARM).
ai-roi-reckoning — corroborated (Gavin Baker + Forward Guidance): the drawdown is a credit-fear/flow event on accelerating fundamentals; installed-base repricing self-funds the build-out, lowering the credit-break probability; credit tell (Meta bond pricing, NVDA CDS) real but "banks hedging." Constructive on the consumption-compute leg (MU/TSM).
token-price-inflation-favors-asset-heavy-compute — independent supply-inelasticity leg (Dwarkesh: ASML-EUV-bound 3× ceiling; spot +40%) + a second operator on GPU-rental repricing (Baker +50–60%). Three sources across two source types now; weakness ("one year ≠ regime") stands.
picks-and-shovels-leading-edge-fab-buildout (high) — outside, no-semicap-book source names ASML EUV throughput as the binding compute ceiling to 2030.
us-biotech-strategic-technology-offshoring — breadth (healthcare): XBI +24% YTD, FDA turnover now a tailwind, IPO window reopened, $300B patent-cliff LOE → big-pharma M&A floor under XBI.

Contradicted / weakened

eplontersen-failure-to-alnylam-silencer-consolidation — contradiction-to-watch: "Alnylam shares dropping 30% following disappointing updated guidance" (Biotech Hangout, show-note level — cause unparsed). Step 2 "perceived winner" marked weakened pending detail; not a calibration yet (pull the ALNY primary next).
4e gate: 23 live rows; 1 flag <−10% sector — TJX −13.1% — medium-tier (~0.40), below the high/med-high gate → 0 auto-calibrations. PWR med-high is −9.1% (above threshold; stock now rising post-Q2). Best live sector-excess: AMZN +19.0% (visible-ROI twin), NXE +8.8%, DNN +6.4%. Worst cluster: critical-minerals −14.9% return / +1.2% sector (picks beat a de-rated theme).

Open questions worth a human's eye

Is Gavin Baker's "installed-base reprices up as contracts roll off" the real reason the build-out can self-fund — or does a demand wobble turn the same leverage into the fast unwind he warns "happened to the Internet"? Watch CDS/spreads + GPU rental prints.
Does ARM's pivot to selling the AGI CPU (merchant silicon, FY2028 split-out) re-rate it beyond the royalty multiple — or does execution-as-a-chip-vendor risk (high-30s/low-40s first-gen GM) cap it?
Does the biotech patent-cliff M&A bid ($300B LOE) actually put a floor under XBI, or is FDA-turnover-as-tailwind the fragile leg if a permanent commissioner reverses posture?

What I looked at

Run status: headless; steps 0.5–7 in-turn; price fetch paced 8/min — 49/49 priced, 0 429s. Weekly ledger (4d) not due. Per-concept bull/base/bear narratives carried forward (headless budget); load-bearing marks in the feed + tables.
Breadth (2a): ai-infrastructure 47% ⚠ over (45 distinct chains) → net-new steered away from AI-infra; the healthcare breadth source (Biotech Hangout) folded to an existing concept. No new hypothesis pages (well-connected wiki).
Ingestion veins (0.5–0.7): podcast 4 (Dwarkesh compute-prices; ILtB Gavin Baker; Forward Guidance AI-unwind; Biotech Hangout — all diarized, ~$0.53); earnings 1 (ARM Q1 FY2027; MP Aug 6, CEG/CF/LLY Aug 5–7 not yet reported; rest have Q2); feeds 0 (SemiAnalysis "Kimi K3" paywalled-partial; CP 08-01 roundup; FK teaser; Apricitas none). Skipped 2 Capital Allocators Annie-Duke replays (no chain).
Steps 1–2b: external autoresearch deferred (5 fresh first-party/analyst sources were the day's research input; protect headless completion). prospect-chains: 0 novel auto-drafts (well-connected wiki).
Sources: 5 promoted + 5 ingested → 3 person-entities created (jason-child, graig-suvannavejh, quinn), 3 updated (gavin-baker, dwarkesh-patel, rene-haas); 1 entity updated (arm-holdings); 0 new mechanisms, 1 materially strengthened (vera-cpu low-med→med), 4 concepts corroborated; 1 contradiction flagged (ALNY).
Live feedback (4e): 23 records + 1 TSLA side bet; 1 flag <−10% sector (TJX), 0 auto-calibrations (medium-tier). chain channel −1.4% avg sector; catalyst channel +4.0%.
Signal feed (7): full active/armed set re-marked 08-04; as_of re-dated only for ARM (vera-cpu, the one row whose research moved) + conviction 0.42→0.48.

stock-market